Adicet Bio rises on cancer therapy trial safety, efficacy data

ADICET Bio

03/11/2022 18:07

** Shares of drug developer Adicet Bio Inc  ACET.O  rise
5.7% to $18.3 
    ** Co updates on safety and efficacy data from its
early-stage trial for ADI-001 in treating aggressive B-cell
Non-Hodgkin’s Lymphoma (NHL)
    ** NHL is a cancer of B cells which are part of the immune
system
    ** Co says ADI-001 continued to demonstrate a favorable
safety and tolerability profile
    ** ACET says ADI-001 showed a 78% overall and complete
response rate and sustained durability in patients, including
those previously exposed to CAR T cancer therapy 
    ** Adds clinical data for the trial will be presented in a
poster presentation meeting on Dec. 10
    ** ACET also says it is on track to initiate a potentially
pivotal program for ADI-001 in the first half of 2023 
    ** Including session gain, stock up 4.4% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain2thomsonreuters.com;))